Tecentriq
E46710
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
Observed surface forms (2)
| Surface form | Occurrences |
|---|---|
| PD-L1 | 1 |
| atezolizumab | 1 |
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
cancer immunotherapy
ⓘ
immune checkpoint inhibitor ⓘ monoclonal antibody ⓘ pharmaceutical drug ⓘ |
| administrationSchedule | given every 2 to 4 weeks depending on regimen ⓘ |
| ATCCode | L01FF03 ⓘ |
| belongsToCompanyPortfolio | Roche ⓘ |
| bindsTo | programmed death-ligand 1 ⓘ |
| canBeUsedInCombinationWith |
bevacizumab
ⓘ
chemotherapy ⓘ |
| commonAdverseEffect |
decreased appetite
ⓘ
fatigue ⓘ nausea ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| drugClass |
anti-PD-L1 antibody
ⓘ
checkpoint inhibitor ⓘ |
| firstFDAApprovalYear | 2016 ⓘ |
| hasActiveIngredient | atezolizumab ⓘ |
| hasInternationalNonproprietaryName |
Tecentriq
self-linksurface differs
ⓘ
surface form:
atezolizumab
|
| immuneRelatedAdverseEffect |
colitis
ⓘ
endocrinopathies ⓘ hepatitis ⓘ pneumonitis ⓘ |
| indication |
hepatocellular carcinoma
ⓘ
melanoma ⓘ non-small cell lung cancer ⓘ small cell lung cancer ⓘ triple-negative breast cancer ⓘ urothelial carcinoma ⓘ various solid tumors expressing PD-L1 ⓘ |
| indicationSubtype |
locally advanced or metastatic urothelial carcinoma
ⓘ
metastatic non-small cell lung cancer ⓘ |
| isUsedAs |
first-line cancer therapy in certain indications
ⓘ
second-line cancer therapy in certain indications ⓘ |
| mechanismOfAction |
blocks interaction between PD-L1 and PD-1
ⓘ
enhances T-cell mediated immune response against tumor cells ⓘ |
| molecularType | humanized monoclonal antibody ⓘ |
| regulatoryApproval |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| regulatoryStatus | prescription-only medicine ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
Tecentriq
self-linksurface differs
ⓘ
surface form:
PD-L1
|
| targetSpecies | human ⓘ |
| therapeuticArea |
immuno-oncology
ⓘ
oncology ⓘ |
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.